Opdivo Extends Survival in Pretreated Advanced Stomach Cancer Patients, Phase 3 Trial Results Show
Categories
The immune checkpoint inhibitor Opdivo (nivolumab) may be a safe and effective treatment for people with advanced gastric or esophagogastric junction cancer who failed standard chemotherapy regimens, results from a Phase 3 clinical trial suggest.